ArticleJournal of computer-aided molecular design2025
Anticancer potential of 2,2'-bipyridine hydroxamic acid derivatives in head and neck cancer therapy.
Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genesis of head and neck cancer (HNC) is attributed to the combined influence of genetic and epigenetic irregularities. While surgical resection and radiotherapy remain primary treatment modalities, the effectiveness of current chemotherapeutic options is often hindered by toxicity, resistance, and limited selectivity. Hydroxyurea has long been recognized for its anticancer potential; however, its clinical application is limited by a short half-life, dose-dependent toxicity, and resistance mechanisms. To address these limitations, researchers have focused on developing novel hydroxyurea derivatives with improved pharmacokinetics, target specificity, and multimodal mechanisms of action. In the present study, we report the design and synthesis of two novel 2,2'-bipyridine hydroxamic acid derivatives, including a hydroxyurea analogue aimed at enhancing chemotherapeutic efficacy and safety. Compound 1A demonstrated selective cytotoxicity against Cal27 cells (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.